StoxEmcure Pharmaceuticals vs Ajanta Pharmaceuticals: share price & financials comparison
NSE: EMCURE vs AJANTPHARM · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Emcure Pharmaceuticals vs Ajanta Pharmaceuticals at a glance
Emcure Pharmaceuticals (EMCURE) has a market capitalisation of ₹41,979 Cr, against ₹41,462 Cr for Ajanta Pharmaceuticals (AJANTPHARM). Over the past year Emcure Pharmaceuticals has returned +65.2%, compared with +34.4% for Ajanta Pharmaceuticals. On valuation, Ajanta Pharmaceuticals trades at a lower P/E of 32.9 versus 38.4. Ajanta Pharmaceuticals earns a higher return on equity (25.9% vs 20.5%). Emcure Pharmaceuticals comes out ahead on momentum and technicals. Ajanta Pharmaceuticals comes out ahead on size, valuation, profitability, growth and financial health. Across the scored metrics below, Emcure Pharmaceuticals leads on 5 and Ajanta Pharmaceuticals on 9. On StoxGud's 10-point checklist, Emcure Pharmaceuticals scores 9/10 and Ajanta Pharmaceuticals scores 9/10.
| Metric | Emcure Pharmaceuticals | Ajanta Pharmaceuticals |
|---|---|---|
| Size | ||
| Market cap | ₹41,979 Cr | ₹41,462 Cr |
| Revenue (latest FY) | ₹9,204 Cr | ₹5,453 Cr |
| Net profit (latest FY) | ₹924 Cr | ₹1,056 Cr |
| Valuation | ||
| P/E | 38.4 | 32.9 |
| P/B | 7.86 | 8.53 |
| Dividend yield | 0.14% | 0.84% |
| Profitability | ||
| Return on equity | 20.5% | 25.9% |
| Net profit margin | 10.7% | 20.2% |
| Operating margin | 20.4% | 27.1% |
| Growth | ||
| Revenue growth (YoY) | +24.3% | +32.5% |
| Net profit growth (YoY) | +33.7% | +49.2% |
| Revenue CAGR (multi-year) | — | +13.5% |
| Financial health | ||
| Debt to equity | 0.27 | 0.02 |
| Momentum | ||
| 1-month return | +15.4% | -7.3% |
| 1-year return | +65.2% | +34.4% |
| 3-year CAGR | — | +22.1% |
| 5-year CAGR | — | +17.9% |
| 10-year CAGR | — | +10.0% |
| Distance from 52W high | -1.4% | -11.0% |
| Technicals | ||
| RSI (14) | 81 | 48 |
| Price vs 200-day avg | +27.3% | +4.1% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Emcure Pharmaceuticals | Ajanta Pharmaceuticals |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 9/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Emcure Pharmaceuticals or Ajanta Pharmaceuticals?
Emcure Pharmaceuticals has a market cap of ₹41,979 Cr and Ajanta Pharmaceuticals has a market cap of ₹41,462 Cr as of 06 Nov 2026.
Which has a lower P/E, Emcure Pharmaceuticals or Ajanta Pharmaceuticals?
Ajanta Pharmaceuticals has the lower P/E: Emcure Pharmaceuticals trades at 38.4 and Ajanta Pharmaceuticals at 32.9.
Which gave better returns in the last year, Emcure Pharmaceuticals or Ajanta Pharmaceuticals?
Emcure Pharmaceuticals did better: Emcure Pharmaceuticals returned +65.2% and Ajanta Pharmaceuticals returned +34.4% over one year.
Is Emcure Pharmaceuticals or Ajanta Pharmaceuticals a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Emcure Pharmaceuticals scores 9/10 and Ajanta Pharmaceuticals scores 9/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.